Prof. Dr. med. Dr. med. habil. Sigmund Silber
FESC, FACC, FAHA
Kardiologe

321

Yeh RW, Silber S, Chen L, Chen S, Hiremath S, Neumann FJ, Qiao S, Saito S, Xu B, Yang Y, Mauri L.
5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program
JACC Cardiovasc Interv. 2017;10:247-254
privater Sonderdruck


320

Cutlip DE, Garratt KN, Novack V, Barakat M, Meraj P, Maillard L, Erglis A, Jauhar R, Popma JJ, Stoler R, Silber S
9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System
JACC Cardiovasc Interv. 2017;10:160-167
privater Sonderdruck


319

Fajadet J, Neumann FJ, Hildick-Smith D, Petronio S, Zaman A, Spence M, Wohrle J, Elhadad S, Roberts D, Hovasse T, Valdes M, Silber S.
Twelve-Month Results of A Prospective, Multicentre Trial to Assess the Everolimus-Eluting Coronary Stent System (Promus Element): The PLATINUM PLUS All Comers Randomised Trial.
EuroIntervention. 2017;12:1595-1604
privater Sonderdruck


318

Di Mario C, Serruys PW, Silber S, Lu S, Wang W, Widimsky P, Xu B, Windecker S.
Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Comers Trial and the RESOLUTE Global Clinical Trial Program.
EuroIntervention,  2016;12:1207-1214
privater Sonderdruck


317

Silber S, Witzenbichler B, Vester E.
Optimale orale Thrombozytenaggregationshemmung (TAH) bei Patienten mit und nach akutem Koronarsyndrom (ACS):
Wann beginnen, womit und wie lange?

Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V.,
Update, 3. Version, Herbst 2016
privater Sonderdruck


316

Helms TM, Silber S, Schäfer A, Masuhr F, Palm F, Darius H, Schrör K, Bansch D, Bramlage P, Hankowitz J, Karle CA, Stargardt T, Weil J, Geller JC.
Konsensuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern
Herzschrittmachertherapie & Elektrophysiologie. 2016; 27:295-306
privater Sonderdruck 


315

Pilgrim T, Vranckx P, Valgimigli M, Stefanini GG, Piccolo R, Rat J, Rothenbuhler M, Stortecky S, Raber L, Blochlinger S, Hunziker L, Silber S, Juni P, Serruys PW, Windecker S.
Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction.
Am Heart J. 2016;175:56-65 
privater Sonderdruck 


314

Abdel-Wahab M, Neumann FJ, Serruys PW, Silber S, Leon M, Mauri L, Yeung A, Belardi JA, Widimsky P, Meredith I, Saito S, Richardt G.
Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program
EuroIntervention, 2016, 12:465-472
privater Sonderdruck


313

Piccolo R, Franzone A, Koskinas KC, Raber L, Pilgrim T, Valgimigli M, Stortecky S, Rat-Wirtzler J, Silber S, Serruys PW, Juni P, Heg D, Windecker S.
Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Am J Cardiol. 2016;118:345-352 
privater Sonderdruck 


312

Styllou P,  Silber S.
A case report of the new PolyzeneTM-F COBRA PzFTM Nanocoated Coronary Stent System (NCS): Addressing an unmet clinical need
Cardiovasc Revasc Med, 2016; 17:209-211
privater Sonderdruck


311

Belardi J, Manoharan G, Albertal M, Widimsky P, Neumann FJ, Silber S, Leon MB, Saito S.
The influence of age on clinical outcomes in patients treated with the resolute zotarolimus-eluting stent.
Catheter Cardiovasc Interv. 2016;87:253-261
privater Sonderdruck


310

Koskinas KC, Siontis GC, Piccolo R, Franzone A, Haynes A, Rat-Wirtzler J, Silber S, Serruys PW, Pilgrim T, Raber L, Heg D, Juni P, Windecker S.
Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients
Circ Cardiovasc Interv. 2016;9:e003255
privater Sonderdruck


309


308

Silber S., Witzenbichler B, Vester E.
Optimale orale Thrombozytenaggregationshemmung (TAH) bei Patienten mit und nach akutem Koronarsyndrom (ACS):
Wann beginnen, womit und wie lange?

Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V.,
Update 2015
privater Sonderdruck 


307

Vranckx P, Kalesan B, Stefanini GG, Farooq V, Onuma Y, Silber S, de Vries T, Juni P, Serruys PW, Windecker S.
Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention.
EuroIntervention, 2015;11:171-179
privater Sonderdruck


306

Kelbaek H, Holmvang L, Richardt G, Eberli FR, Stella P, Buszman PE, Neumann FJ, Serruys PW, Windecker S, Widimsky P, Belardi JA, Silber S.
Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions.
EuroIntervention. 2015;11:650-657
privater Sonderdruck


305

Chevalier B, Wijns W, Silber S, Garcia E, Serra A, Paunovic D, Serruys P, investigators N.
Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial.
EuroIntervention. 2015;11:549-554
privater Sonderdruck


304

Dudek D, Dziewierz A, Brener SJ, Abizaid A, Merkely B, Costa RA, Bar E, Rakowski T, Kornowski R, Dressler O, Abizaid A, Silber S, Stone GW.
Mesh-covered embolic protection stent implantation in ST-segment-elevation myocardial infarction: final 1-year clinical and angiographic results from the MGUARD for acute ST elevation reperfusion trial.
Circ Cardiovasc Interv. 2015;8:e001484
privater Sonderdruck


303

Diletti R, Garcia-Garcia HM, Bourantas C, Van Mieghem NM, van Geuns RJ, Muramatsu T, Zhang YJ, Mauri L, Belardi J, Silber S, Widimsky P, Leon M, Windecker S, Meredith I, Neumann FJ, Yeung AC, Saito S, Liu M, van Leeuwen F, Serruys PW.
Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program.
Catheter Cardiovasc Interv. 2015;85:952-958
privater Sonderdruck


302

Piccolo R, Pilgrim T, Heg D, Franzone A, Rat-Wirtzler J, Raber L, Silber S, Serruys PW, Juni P, Windecker S.
Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease: A Patient-Level Pooled Analysis of 6,081 Patients.
JACC Cardiovasc Interv. 2015;8:1657-1666
privater Sonderdruck


301

Costa RA, Abizaid A, Lotan C, Dudek D, Silber S, Dizon JM, Maehara A, Dressler O, Brener SJ, Stone GW.
Impact of thrombus burden on outcomes after standard versus mesh-covered stents in acute myocardial infarction (from the MGuard for acute ST elevation reperfusion trial).
Am J Cardiol. 2015;115:161-166
privater Sonderdruck


300

Silber S.
Stentvergleich bei KHK: Vollständig absorbierbare Stents bringen keinen gesicherten Vorteil

Dtsch Med Wochenschr. 2015;140:386
privater Sonderdruck


299

Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, Negoita M, Buszman PE, Windecker S.
Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial
Circ Cardiovasc Interv. 2015;8:e002230
privater Sonderdruck


298

Bourantas CV, Zhang YJ, Garg S, Iqbal J, Valgimigli M, Windecker S, Mohr FW, Silber S, Vries T, Onuma Y, Garcia-Garcia HM, Morel MA, Serruys PW.
Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials.
Heart, 2014;100:1158-1164
privater Sonderdruck 


297

Vester EG, Bocksch W, Dörr R, Grebe O, Hoffmann S, Leitsch T, Silber S.
Orale Antikoagulation bei interventionellen Eingriffen in der Kardiologie,
Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V.,
Sommer 2014 
privater Sonderdruck 


296

Kotzerke J, Silber S.
Endovascular Brachytherapy to Prevent Restenosis After Percutaneous Coronary Intervention
Buchkapitel in: Therapeutic Nuclear Medicine, Editor: Richard P. Baum,
Springer-Verlag Berlin Heidelberg 2014, ISSN 0942-5373 
privater Sonderdruck 


295

Witt S, Leidl R, Becker C, Holle R, Block M, Brachmann J, Silber S, Stollenwerk B.
The effectiveness of the cardiovascular disease prevention programme 'KardioPro' initiated by a German sickness fund: a time-to-event analysis of routine data.
PLoS One. 2014;9:e114720 
privater Sonderdruck 


294

Leistner DM, Klotsche J, Palm S, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM for the DETECT study group.
Prognostic value of reported chest pain for cardiovascular risk stratification in primary care.
European Journal of Preventive Cardiology. 2014;21:727-738
privater Sonderdruck 


293

Loh JP, Stella PR, Sangiorgi G, Silber S, Stahnke S, von Strandmann RP, Torguson R, Waksman R.
Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.
Cardiovascular Revascularization Medicine, 2014;15:23-28
privater Sonderdruck 


292

Schäfer A, Arntz HR, Boudriot E, Garlichs C, Hoffmann S, Ince H, Klingenheben T, Weil J, Zugck C, Helms TM, Silber S.
Differenzierte antithrombozytäre Therapie bei akutem Koronarsyndrom
Dtsch Med Wochenschr, 1390: 152–158 (2014)
privater Sonderdruck


291

Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, European Society of Cardiology Committee for Practice G, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Committee ECG, Sousa Uva M, Achenbach S, Pepper J, Anyanwu A, Badimon L, Bauersachs J, Baumbach A, Beygui F, Bonaros N, De Carlo M, Deaton C, Dobrev D, Dunning J, Eeckhout E, Gielen S, Hasdai D, Kirchhof P, Luckraz H, Mahrholdt H, Montalescot G, Paparella D, Rastan AJ, Sanmartin M, Sergeant P, Silber S, Tamargo J, ten Berg J, Thiele H, van Geuns RJ, Wagner HO, Wassmann S, Wendler O, Zamorano JL, Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S, European Association of Percutaneous Cardiovascular I.
2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).
Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Eur J Cardiothorac Surg. 2014;46:517-592
privater Sonderdruck 


290

Aljutaili M, Becker C, Witt S, Holle R, Leidl R, Block M, Brachmann J, Silber S, Bestehorn K, Stollenwerk B.
Should health insurers target prevention of cardiovascular disease? A cost-effectiveness analysis of an individualised programme in Germany based on routine data.
BMC Health Serv Res. 2014;14:263
privater Sonderdruck 


289

Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S.
4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
J Am Coll Cardiol. 2014;63:1617-1625
privater Sonderdruck 


288

Stefanini GG, Taniwaki M, Kalesan B, Raber L, Stortecky S, Pilgrim T, Onuma Y, Silber S, Serruys PW, Meier B, Juni P, Windecker S.
The impact of renal impairment on long-term safety and effectiveness of drug-eluting stents.
PLoS One. 2014;9:e106450
privater Sonderdruck 


287

Ferenc M, Kornowski R, Belardi J, Serruys P, Silber S, Widimsky P, Windecker S, Neumann FJ.
Three-year outcomes of percutaneous coronary intervention with next-generation zotarolimus-eluting stents for de novo coronary bifurcation lesions.
J Invasive Cardiol. 2014;26:630-638
privater Sonderdruck


286

Caputo R, Leon M, Serruys P, Neumann FJ, Yeung A, Windecker S, Belardi JA, Silber S, Meredith I, Widimsky P, Saito S, Mauri L.
Performance of the resolute zotarolimus-eluting stent in small vessels.
Catheter Cardiovasc Interv. 2014;84:17-23
privater Sonderdruck 


285

Dudek D, Brener SJ, Rakowski T, Dziewierz A, Abizaid A, Silber S, Yaacoby E, Dizon JM, Costa RA, Maehara A, Dressler O, Stone GW.
Efficacy of an Embolic Protection Stent as a Function of Delay to Reperfusion in ST-Segment Elevation Myocardial Infarction (from the MASTER Trial).
Am J Cardiol. 2014;114:1485-1489
privater Sonderdruck 


284

Silber S, Kirtane AJ, Belardi JA, Liu M, Brar S, Rothman M, Windecker S.
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Eur Heart J. 2014;35:1949-1956
privater Sonderdruck 


283


282

Widimsky P, Motovska Z, Belardi J, Serruys P, Silber S, Windecker S, Neumann FJ.
Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program.
Int J Cardiol. 2013;168:3522-3526  
privater Sonderdruck 


281

Willich SN, Müller-Riemenschneider F, McBride D, Silber S, Kuck KH, Nienaber CA, Schneider S, Senges J, Brüggenjürgen B.
Health economic evaluation of the use of drug-eluting stents : First results from the Drug-Eluting Stent Registry (DES.de).
Herz, 2013; 38:57-64  
privater Sonderdruck 


280

Vranckx P, McFadden E, Cutlip DE, Mehran R, Swart M, Kint PP, Zijlstra F, Silber S, Windecker S, Serruys PW.
Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: methodology and external validation.
Contemporary Clinical Trials. 2013;34:53-59  
privater Sonderdruck 


279

Silber S, Serruys PW, Leon MB, Meredith IT, Windecker S, Neumann FJ, Belardi J, Widimsky P, Massaro J, Novack V, Yeung AC, Saito S, Mauri L.
Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
JACC Cardiovasc Interv. 2013;6:366-377  
privater Sonderdruck 


278

Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P. 
Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
JACC Cardiovasc Interv. 2013;6:905-913  
privater Sonderdruck 


277

Leistner DM, Klotsche J, Pieper L, Palm S, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study.
Clin Res Cardiol. 2013;102:259-268  
privater Sonderdruck 


276

Haude M, Lee SW, Worthley SG, Silber S, Verheye S, Erbs S, Rosli MA, Botelho R, Meredith I, Sim KH, Stella PR, Tan HC, Whitbourn R, Thambar S, Abizaid A, Koh TH, Den Heijer P, Parise H, Cristea E, Maehara A, Mehran R.
The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
JACC Cardiovasc Interv. 2013;6:334-343  
privater Sonderdruck 


275

Farooq V, Vranckx P, Mauri L, Cutlip DE, Belardi J, Silber S, Widimsky P, Leon M, Windecker S, Meredith I, Negoita M, van Leeuwen F, Neumann FJ, Yeung AC, Garcia-Garcia HM, Serruys PW.
Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program.
Heart. 2013;99:626-633  
privater Sonderdruck 


274

Costa JR, Jr., Abizaid A, Dudek D, Silber S, Leon MB, Stone GW.
Rationale and design of the MGuard for acute ST elevation reperfusion MASTER trial.
Catheter Cardiovasc Interv. 2013;82:184-190  
privater Sonderdruck 


273

Bramlage P, Cuneo A, Zeymer U, Hochadel M, Richardt G, Silber S, Senges J, Nienaber CA, Tebbe U, Kuck KH.
Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents.
Clin Res Cardiol. 2013;102:289-297 
privater Sonderdruck 


272

Diletti R, Garcia-Garcia HM, Bourantas CV, van Geuns RJ, Van Mieghem NM, Vranckx P, Zhang YJ, Farooq V, Iqbal J, Wykrzykowska JJ, de Vries T, Swart M, Teunissen Y, Negoita M, van Leeuwen F, Silber S, Windecker S, Serruys PW
Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial.
Heart, 2013;99:1267-1274
privater Sonderdruck


271

Silber S, Basler M, Gerhard N:
Possibilities and obstacles of the German Reimbursement System (G-DRG) for the implementation of guideline-recommended adjunctive technical devices for percutaneous coronary interventions
Confluence, Issue 6, 12 - 15, (2012)  
privater Sonderdruck 


270

Silber S.
The RESOLUTE clinical programme: one month DAPT data presented at TCT
Confluence, Issue 6, 31 - 33, (2012)  
privater Sonderdruck 


269

Labeit AM, Klotsche J, Pieper L, Pittrow D, Einsle F, Stalla GK, Lehnert H, Silber S, Zeiher AM, Marz W, Wehling M, Wittchen HU.
Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients.
PLoS One. 2012;7:e52229  
privater Sonderdruck 


268

Vranckx P, Farooq V, Garg S, Van Es GA, Silber S, Windecker S, Stone GW, Serruys PW.
Different cardiac biomarkers to detect peri-procedural myocardial infarction in contemporary coronary stent trials: impact on outcome reporting.
Heart. 2012;98:1424-1430  
privater Sonderdruck 


267

Stone GW, Abizaid A, Silber S, Dizon JM, Merkely B, Costa RA, Kornowski R, Abizaid A, Wojdyla R, Maehara A, Dressler O, Brener SJ, Bar E, Dudek D:
Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial.
J Am Coll Cardiol, 60:1975–1984 (2012)  
privater Sonderdruck 


266

Stefanini GG, Kalesan B, Pilgrim T, Raber L, Onuma Y, Silber S, Serruys PW, Meier B, Juni P, Windecker S.
Impact of sex on clinical and angiographic outcomes among patients undergoing revascularization with drug-eluting stents.
JACC Cardiovasc Interv; 5:301-310 (2012) 
privater Sonderdruck 


265

Van de Werf F, Ardissino D, Bueno H, Collet JP, Gershlick A, Kolh P, Kristensen SD, Silber S, Verheugt F, Wojakowski W.
Acute coronary syndromes: Considerations for improved acceptance and implementation of management guidelines.
Expert Rev Cardiovasc Ther; 10:489-503 (2012)  
privater Sonderdruck 


264

Neumann FJ, Cremer J, Falk V, Reifart N, Silber S, Thielmann M.
Kommentar zu den gemeinsamen „Guidelines on Myocardial Revascularization“ der European Society of Cardiology (ESC) und der European Association for Cardio-Thoracic Surgery (EACTS)
Der Kardiologe; 6: 94 – 104 (2012)  
privater Sonderdruck 

Pocket Leitlinien Myokardrevaskularisation


263

Abdel-Wahab M, Nienaber CA, Mostafa AE, Ferenc M, Silber S, Sabin G, Tebbe U, Akin I, Hochadel M, Senges J, Kuck KH, Richardt G.
Treatment of coronary bifurcation lesions with drug-eluting stents: Insights from the first phase of the prospective multicenter german drug-eluting stent registry.
J Interv Cardiol. 2012;25:344-352  
privater Sonderdruck 


262

Beijk MA, Damman P, Klomp M, Woudstra P, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter AR.
Twelve-month clinical outcomes after coronary stenting with the genous bio-engineered R stent in patients with a bifurcation lesion: From the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) registry.
Coronary Artery Disease; 23:201-207 (2012)  
privater Sonderdruck 


261

Damman P, Klomp M, Silber S, Beijk MA, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ.
Duration of dual antiplatelet therapy and outcomes after coronary stenting with the genous bio-engineered R stent in patients from the e-HEALING registry.
Catheter Cardiovasc Interv; 79:243-252 (2012)  
privater Sonderdruck 


260

Klomp M, Damman P, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ.
Applying the national institute for clinical excellence criteria to patients treated with the genous bio-engineered R stent: A sub-study of the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry.
Heart Vessels; 27:360-369 (2012)  
privater Sonderdruck 


259

Leistner DM, Klotsche J, Palm S, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Resting heart rate as a tool for risk stratification in primary care: Does it provide incremental prognostic information?
European Journal of Preventive Cardiology; 19:275-284 (2012)
privater Sonderdruck 


258

Leistner DM, Klotsche J, Pieper L, Stalla GK, Lehnert H, Silber S, März W, Wittchen HU, Zeiher AM.
Circulating troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention.
Clin Chem; 58:200-208 (2012)  
privater Sonderdruck 


257

Klomp M, Damman P, Beijk MA, Tan KH, Balian V, de Luca G, Tijssen JG, Silber S, de Winter RJ.
Differences in cardiovascular risk factors and clinical outcomes between western european and southeast asian patients treated with the genous bio-engineered R stent: An e-HEALING worldwide registry substudy.
Coronary Artery Disease; 23:271-277 (2012)  
privater Sonderdruck 


256

Silber S, Tan HC, Iniguez A, Scacciatella P, Smith D, Kutryk M, Brugaletta S 
Relative clinical contraindications to the use of drug-eluting stents: what are the alternatives?
Cardiology International, 45 - 48 (2012)  
privater Sonderdruck 


255

Schneider HJ, Klotsche J, Friedrich N, Schipf S, Volzke H, Silber S, Marz W, Nauck M, Pittrow D, Wehling M, Sievers C, Lehnert H, Stalla GK, Wittchen HU, Wallaschofski H.
Risk factors associated with the metabolic syndrome in abdominal obesity.
Clin Obes. 2012;2:142-149  
privater Sonderdruck 


254

Silber S, Helms T, Berger H-J, Braun P, Hoffmann S, Schäfer A, Vester E.
Optimale Thrombozytenaggregationshemmung bei Patienten mit akutem Koronarsyndrom (ACS).
Eine Therapieempfehlung des BIK - Berufsverband Interventioneller Kardiologen - e.V.,
1. Version, Frühjahr 2012
privater Sonderdruck 


253

Alfons Schuhbeck im Gespräch mit dem Kardiologen Prof. Dr. med. Sigmund Silber
Die richtige Ernährung für Herz und Kreislauf

Buchkapitel in: A. Schuhbeck: Die Heilkraft von Omega-3, Seiten 24 - 27
Verlag Zabert Sandmann GmbH, München, 1. Auflage 2011, ISBN 978-3-89883-273-1


252

Nationale Versorgungsleitlinien der Bundesärztekammer, Kassenärztlichen Bundesvereinigung und der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften zur chronischen koronaren Herzkrankheit
2011
www.versorgungsleitlinien.de


251

Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK
Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: Insights from the EURO HEART survey PCI registry.
Catheter Cardiovasc Interv; 78:702-709 (2011)  
privater Sonderdruck 


250

Bauer T, Nienaber CA, Akin I, Kuck KH, Hochadel M, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Zahn R.
Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: Results from the German DES.DE-Registry.
Clin Res Cardiol; 100:701-709 (2011)
privater Sonderdruck


249

Damman P, Iniguez A, Klomp M, Beijk M, Woudstra P, Silber S, Ribeiro EE, Suryapranata H, Sim KH, Tijssen JG, de Winter RJ.
Coronary stenting with the genous bio-engineered R stent in elderly patients.
Circ J; 75:2590-2597 (2011)
privater Sonderdruck


248

Damman P, Klomp M, Beijk MA, Silber S, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Sim KH, Tijssen JG, de Winter RJ. 
Twelve-month outcomes after coronary stenting with the genous bio-engineered R stent in diabetic patients from the e-HEALING registry.
J Interv Cardiol; 24:285-294 (2011)
privater Sonderdruck 


247

De Mulder M, Gitt A, van Domburg R, Hochadel M, Seabra-Gomes R, Serruys PW, Silber S, Weidinger F, Wijns W, Zeymer U, Hamm C, Boersma E.
Euroheart score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary intervention.
Eur Heart J; 32:1398-1408 (2011)
privater Sonderdruck 


246

den Dekker WK, Houtgraaf JH, Onuma Y, Benit E, de Winter RJ, Wijns W, Grisold M, Verheye S, Silber S, Teiger E, Rowland SM, Ligtenberg E, Hill J, Wiemer M, den Heijer P, Rensing BJ, Channon KM, Serruys PW, Duckers HJ.
Final results of the HEALING-IIb trial to evaluate a bio-engineered cd34 antibody coated stent (Genous stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients.
Atherosclerosis; 219:245-252 (2011)
privater Sonderdruck


245

Garg S, Serruys PW, Silber S, Wykrzykowska J, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Van Remortel E, Ronden J, Windecker S.
The prognostic utility of the syntax score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial.
JACC Cardiovasc Interv; 4:432-441 (2011)  
privater Sonderdruck 


244

Gomez-Lara J, Heo JH, Brugaletta S, Garg S, Garcia-Garcia HM, van Geuns RJ, Silber S, Windecker S, Serruys PW.
Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents.
Am Heart J; 162:1069-1079 e1062 (2011)
privater Sonderdruck


243

Gutierrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbaek H, Saunamaki K, Escaned J, Gonzalo N, di Mario C, Borgia F, Nuesch E, Garcia-Garcia HM, Silber S, Windecker S, Serruys PW.
Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. A fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: An optical coherence tomography substudy from the resolute all comers trial.
Eur Heart J; 32:2454-2463 (2011)
privater Sonderdruck


242

Schneider HJ, Klotsche J, Silber S, Stalla GK, Wittchen HU.
Measuring abdominal obesity: Effects of height on distribution of cardiometabolic risk factors risk using waist circumference and waist-to-height ratio.
Diabetes Care; 34:e7 (2011)
privater Sonderdruck


241

Silber S, Damman P, Klomp M, Beijk MA, Grisold M, Ribeiro EE, Suryapranata H, Wojcik J, Hian Sim K, Tijssen JG, de Winter RJ.
Clinical results after coronary stenting with the genous bio-engineered R stent: 12-month outcomes of the e-HEALING (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry.
EuroIntervention; 6:819-825 (2011)
privater Sonderdruck


240

Silber S, Gutierrez-Chico JL, Behrens S, Witzenbichler B, Wiemer M, Hoffmann S, Slagboom T, Harald D, Suryapranata H, Nienaber C, Chevalier B, Serruys PW.
Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: The EUROSTAR-II randomised clinical trial.
EuroIntervention; 7:64-73 (2011)
privater Sonderdruck


239

Silber S, Helms TM, Garlichs C, Arntz HR, Weil J, Ince H, Klingenheben T, Hoffmann S, Boudriot E, Steiger H, Zugck C.
Prasugrel in der Akut- und Nachbehandlung des akuten Koronarsyndroms: Wie ist der aktuelle Stand?
Dtsch Med Wochenschr; 136:782-785 (2011)  
privater Sonderdruck 


238

Silber S, Windecker S, Vranckx P, Serruys PW. 
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the resolute all comers trial
Lancet; 377:1241-1247 (2011)  
privater Sonderdruck 


237

Stefanini GG, Serruys PW, Silber S, Khattab AA, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli AL, Gobbens P, Windecker S.
The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the resolute all comers trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention).
J Am Coll Cardiol; 57:2221-2232 (2011)
privater Sonderdruck


236

Stella PR, Belkacemi A, Waksman R, Stahnke S, Torguson R, von Strandmann RP, Agostoni P, Sangiorgi G, Silber S. 
The VALENTINES trial: Results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation dior paclitaxel drug-eluting balloon for in-stent restenosis treatment.
EuroIntervention; 7:705-710 (2011)
privater Sonderdruck


235

Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK.
Predictors of hospital mortality in the elderly undergoing percutaneous coronary intervention for acute coronary syndromes and stable angina.
Int J Cardiol; 151:164-169 (2011)
privater Sonderdruck 


234

Silber S.
Immediate and Long-Term Therapy of Patients with Acute Coronary Syndromes with Thienopyridines. Current Status According to the Latest European Society of Cardiology (ESC) Guidelines
RMMJ; 2: e0056 (2011)  
privater Sonderdruck 


233

Silber S,Van de Werf F. and Members of the Task Force
ESC/DGK Pocket-Leitlinie:
Akutes Koronarsyndrom mit persistierender ST- Streckenhebung (STEMI) 
Der Kardiologe; 4:93-106 (2010)
privater Sonderdruck 


232

Silber S, Borggrefe M, Hasenfuß G, Falk V, Kastrati A, Weis M, Hamm CW.
Kommentare zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie von Patienten mit ST-Streckenhebungsinfarkt (STEMI)
Der Kardiologe; 4:84-92 (2010)
privater Sonderdruck 


231

Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, Serruys P, Vahanian A, Silber S, Wijns W, Hochadel M, Nef HM, Hamm CW, Marco J, Gitt AK.
Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: Impact of clinical status and procedural characteristics.
Clin Res Cardiol; 99:375-383 (2010)
privater Sonderdruck


230

Mahabadi AA, Achenbach S, Burgstahler C, Dill T, Fischbach R, Knez A, Moshage W, Richartz BM, Ropers D, Schröder S, Silber S, Möhlenkamp S.
Safety, efficacy, and indications of beta-adrenergic receptor blockade to reduce heart rate prior to coronary ct angiography.
Radiology; 257:614-623 (2010)
privater Sonderdruck


229

Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, John U, Dorr M, Felix S, Lehnert H, Pittrow D, Silber S, Volzke H, Stalla GK, Wallaschofski H, Wittchen HU.
The predictive value of different measures of obesity for incident cardiovascular events and mortality.
J Clin Endocrinol Metab; 95:1777-1785 (2010)
privater Sonderdruck


228

Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S.
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
N Engl J Med; 363:136-146 (2010) 
privater Sonderdruck Originalarbeit
privater Sonderdruck Appendix


227

Silber S. 
Evidenzbasiertes Vorgehen beim ST-Strecken- Hebungsinfarkt (STEMI): Neueste Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) 2010
Herz; 35:558-564 (2010)
privater Sonderdruck


226

Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW.
Myocardial infarction adjudication in contemporary all-comer stent trials: Balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies.
EuroIntervention; 5:871-874 (2010)
privater Sonderdruck


225

Hoffmeister HH, Bode C, Darius H, Huber K, Rybak K, Silber S.
Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen
Positionspapier der Deutschen Gesellschaft für Kardiologie (DGK)
Der Kardiologe; 4: 365-374 (2010)
privater Sonderdruck


224

Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D.
Guidelines on Myocardial Revascularization of the European Society of Cardiology (ESC)
Eur Heart J; 31:2501-2555 (2010)
privater Sonderdruck
Eur J Cardiothorac Surg. 2010;38 Suppl:S1-S52
privater Sonderdruck